Literature DB >> 28223669

[Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].

Kumiko Kida1, Michiko Murai, Hideko Yamauchi.   

Abstract

Of all breast cancer cases, 5-10% occur because of inherited germline mutation. For hereditary breast and ovarian cancer (HBOC)syndrome, congenital knowledge and strategies for breast cancer treatment and risk reduction are necessary. Regarding the surgical procedure for the cancer site, the ipsilateral breast tumor recurrence rate following breast-conserving surgery in breast cancers with BRCA1/2 mutation is not significantly higher than that in sporadic breast cancers. In addition, prognosis did not differ according to surgical methods. Therefore, breast-conserving surgery for HBOC is not an absolute contraindication, although the risk of developing new primary tumors in the long term should be carefully considered. For the contralateral breast, 3 choices are available, surveillance, chemo-prevention, and risk-reducing mastectomy. Risk-reducing mastectomy is known to decrease the risk of breast cancer by 90%. Genetic counseling is essential for decision making in HBOC treatment. In this review, we reevaluated the current evidence for surgical decision making and systemic therapies for HBOC syndrome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28223669

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.

Authors:  Cathy Su; Jeffrey P Gius; Julia Van Steenberg; Alexis H Haskins; Kazuki Heishima; Chisato Omata; Masahiro Iwayama; Mami Murakami; Takashi Mori; Kohji Maruo; Takamitsu A Kato
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.